High-dose @entity440 and sulindac as first-line treatment for XXXX .

@entity1 @entity440 @entity66 @entity5 @entity765 @entity1412
BACKGROUND: @entity765 are mesenchymal nonmetastasizing @entity5 . Although rare in the general population, they are a common extracolonic manifestation of @entity1412 ( @entity1412 ). Because of high @entity5 recurrence rates, surgery has been less than satisfactory in the treatment of @entity765 . In the current study, high doses of @entity440 in combination with sulindac were used to treat severe @entity765 to avoid surgery. METHODS: Since 1992, 25 @entity1 at Heinrich Heine University (Dusseldorf, Germany) were treated with a combination of @entity440 and sulindac. In the current study, 17 @entity1 with @entity1412 -associated and 8 @entity1 with sporadic @entity765 received 120 mg of @entity440 and 300 mg of sulindac daily. Every 6 months, the protracted course of desmoid growth was measured by computed tomography and/or magnetic resonance imaging scans. @entity5 responses were characterized as @entity66 ( @entity66 ), partial regression (PR), and complete regression (CR). RESULTS: Of the group of @entity1 who received @entity440 and sulindac as a primary treatment, all three @entity1 with sporadic @entity765 demonstrated cessation of growth, and 10 of the 13 @entity1 with @entity1412 -associated @entity5 achieved either a PR or CR. In the @entity765 group, eight of nine @entity1 developed @entity5 recurrences after undergoing surgery at other institutions. Of these, two @entity1 had @entity66 and two @entity1 had a PR to CR. CONCLUSIONS: The @entity1 with @entity765 who were managed conservatively with high-dose @entity440 and sulindac had the best outcome. @entity765 recurrence after surgery was high and in the @entity1412 -associated @entity5 group, therapy with @entity440 and sulindac was found to be less successful. Based on this experience, the authors recommended high-dose @entity440 and sulindac as the primary treatment for @entity1 with @entity1412 -associated @entity765 . However, to our knowledge, the best approach after surgical intervention for @entity1 with sporadic @entity765 remains to be determined.
